par Fracassi, Anna;Marangoni, Martina ;Rosso, Pamela;Pallottini, Valentina;Fioramonti, Marco ;Siteni, Silvia;Segatto, Marco
Référence Current neuropharmacology
Publication Publié, 2017
Référence Current neuropharmacology
Publication Publié, 2017
Article révisé par les pairs
Résumé : | Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions. |